3 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Renal Cell Cancer Metastatic: new trials by email Literature Review of Renal Cell Cancer Metastatic trials Research Report on Renal Cell Cancer Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-10-15 | 2026-10-13 |
| Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue meldonium - Renal Cell Cancer Metastatic, Kidney Cancer | Phase 1 / Phase 2 | Completed | Kidney Cancer Research Bureau | 60 | 2022-02-01 | 2024-10-18 |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors EU101 - Solid Tumor, Renal Cell Cancer Metastatic | Phase 1 / Phase 2 | Unknown | Eutilex | 110 | 2021-05-31 | 2024-03-15 |
| Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. Nivolumab - Renal Cell Cancer Metastatic, Non-small Cell Lung Cancer Metastatic | Phase 2 | Completed | Kidney Cancer Research Bureau | 26 | 2020-08-10 | 2023-03-08 |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Belzutifan, Cabozantinib - Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 2 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 118 | 2018-09-27 | 2024-12-20 |
| A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC CT053PTSA - Renal Cell Cancer Metastatic | Phase 1 / Phase 2 | Terminated | Sunshine Lake Pharma Co., Ltd. | 10 | 2018-06-25 | 2021-03-24 |
| Interleukin-2 in Metastatic Kidney Cancer Interleukin-2 - Renal Cell Cancer Metastatic, Kidney Cancer Metastatic | Phase 2 | Terminated | Western Regional Medical Center | 7 | 2012-09-01 | 2018-02-08 |
| 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer 5-Fluorouracil and Interferon - Gastrointestinal Cancer Metastatic, Renal Cell Cancer Metastatic | Phase 2 | Completed | Western Regional Medical Center | 18 | 2012-07-01 | 2018-03-21 |
Kidney Neoplasms (4) · Carcinoma, Renal Cell (3) · Recurrence (2) · Carcinoma, Non-Small-Cell Lung (1) · Pleural Effusion, Malignant (1) · Prostatic Neoplasms (1)
Neoplasms (6) · Neoplasms by Site (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5) · Male Urogenital Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Urologic Diseases (5) · Urologic Neoplasms (5) · Adenocarcinoma (3) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Disease Attributes (2)
3-(2,2,2-trimethylhydrazine)propionate (1) · Fluorouracil (1) · Interferons (1) · Interleukin-2 (1) · Nivolumab (1) · belzutifan (1) · cabozantinib (1)
Kidney Cancer Research Bureau (2) · Western Regional Medical Center (2) · Eutilex (1) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Sunshine Lake Pharma Co., Ltd. (1) · Telix Pharmaceuticals (Innovations) Pty Limited (1)
United States (5) · Russia (2) · Albania (1) · Azerbaijan (1) · China (1) · South Korea (1)
Walter Quan, MD (2) · Guo Jun, PhD (1) · Ilya Tsimafeyeu, M.D. (1)
PMID 22980441, PMID 26706103, PMID 37011650, PMID 38172595, PMID 39756444
2025 (1)